Clinical Trial Update: A Trial of AK112 (PD-1/VEGF Bispecific Antibody) in Patients With NSCLC [Phase 1, Phase 2]

View source ↗

Summary

The trial update indicates completion of a Phase 1/2 study evaluating AK112, a PD-1/VEGF bispecific antibody, in patients with non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AK112

Snippet

Sponsor: Akeso | Conditions: Non-small Cell Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED